0000950170-23-000394.txt : 20230109 0000950170-23-000394.hdr.sgml : 20230109 20230109060332 ACCESSION NUMBER: 0000950170-23-000394 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230109 DATE AS OF CHANGE: 20230109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RxSight, Inc. CENTRAL INDEX KEY: 0001111485 STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851] IRS NUMBER: 943268801 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40690 FILM NUMBER: 23516397 BUSINESS ADDRESS: STREET 1: 100 COLUMBIA STREET STREET 2: SUITE 120 CITY: ALISO VIEJO STATE: CA ZIP: 92656 BUSINESS PHONE: 949-521-7822 MAIL ADDRESS: STREET 1: 100 COLUMBIA STREET STREET 2: SUITE 120 CITY: ALISO VIEJO STATE: CA ZIP: 92656 FORMER COMPANY: FORMER CONFORMED NAME: CALHOUN VISION INC DATE OF NAME CHANGE: 20000410 8-K 1 rxst-20230108.htm 8-K 8-K
false000111148500011114852023-01-082023-01-08

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 08, 2023

 

 

RxSight, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40690

94-3268801

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

100 Columbia

 

Aliso Viejo, California

 

92656

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 949 521-7830

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

RXST

 

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On January 8, 2023, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited fourth quarter and full-year 2022 financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1.

 

In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01 Other Events.

 

On January 8, 2023, the Company reported the following preliminary unaudited fourth quarter and full year 2022 financial and operational results:

 

•
Preliminary unaudited fourth quarter 2022 revenue is expected to be approximately $16.1 million, representing growth of approximately 91% compared to the prior year period, driven by:
o
The sale of 57 Light Delivery Devices (LDD™s), expanding the installed base to 400 LDDs as of December 31, 2022; and
o
The sale of 9,123 Light Adjustable Lenses (LAL®s).
•
Preliminary unaudited revenue for 2022 is expected to be approximately $49.0 million, representing growth of approximately 117% compared to the prior year, driven by:
o
The sale of 195 LDDs; and
o
The sale of 25,284 LALs.

 

Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2022, is expected to be $105.8 million, which includes $6.0 million in net proceeds from sales of shares of the Company’s common stock sold through the Company’s “at-the-market” offering during the fourth quarter of 2022.


 

The foregoing financial and operational results are preliminary estimates. The Company is in the process of finalizing its financial statements for the year ended December 31, 2022, and its actual results remain subject to completion of those financial statements and their audit by the Company’s independent registered public accounting firm. These preliminary estimates are based on information currently available to management, and certain related assumptions, and are not a comprehensive statement of our financial or operational results for the quarter or year ended December 31, 2022. The Company’s actual, reported results of operations could differ materially from these estimates based on completion of its year end closing procedures, final adjustments and developments that may arise prior to completion of its annual financial statements, and adjustments arising from the audit by the Company’s independent registered public accounting firm. You should carefully review our audited, consolidated financial statements for the year ended December 31, 2022, when they become available. Audited full-year 2022 and unaudited fourth quarter 2022 financial results are anticipated to be announced in early March 2023.

Forward-Looking Statements



This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning our preliminary unaudited fourth quarter and full-year 2022 financial and operational results and the anticipated timing for announcement of our unaudited fourth quarter and audited full-year 2022 financial results. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. Investors should review the risks and uncertainties contained in our filings with the Securities and Exchange Commission (“SEC”), including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the SEC on November 7, 2022, as well as other risks set forth in our other filings with the SEC. We caution you that the forward-looking information presented in this Current Report on Form 8-K is not a guarantee of future events, and that actual events may differ materially from those described in or suggested by the forward-looking information contained in this Current Report on Form 8-K. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other similar terminology. Any forward-looking information presented herein is made

only as of the date of this Current Report on Form 8-K, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

Item 9.01 Financial Statements and Exhibits.

 

Exhibit number

 

Description

99.1

 

Press Release dated January 8, 2023.

104

 

Cover Page Interactive Data File (embedded within the inline XBRL document).

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

RxSight, Inc.

 

 

 

 

Date:

January 9, 2023

By:

/s/ Shelley Thunen

 

 

 

Name: Shelley Thunen
Title: Chief Financial Officer

 

 EX-99.1 2 rxst-ex99_1.htm EX-99.1 EX-99.1

img261313502_0.jpg 

 

Exhibit 99.1

 

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial and Operational Results

 

Aliso Viejo, Calif. (NASDAQ: RXST) – January 8, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2022.

 

Preliminary Unaudited Results

•
Preliminary unaudited fourth quarter 2022 revenue is expected to be approximately $16.1 million, representing growth of approximately 91% compared to the prior year period, driven by:
o
The sale of 57 Light Delivery Devices (LDD™s), expanding the installed base to 400 LDDs as of December 31, 2022; and
o
The sale of 9,123 Light Adjustable Lenses (LAL®s).
•
Preliminary unaudited 2022 fiscal year revenue is expected to be approximately $49.0 million, representing growth of approximately 117% compared to the prior year, driven by:
o
The sale of 195 LDDs; and
o
The sale of 25,284 LALs.
•
Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2022, is expected to be $105.8 million, which includes $6.0 million in net proceeds from sales of shares of the Company’s common stock sold through the Company’s “at-the-market” (“ATM”) offering during the fourth quarter of 2022.

 

“Our fourth quarter financial results demonstrate that cataract patients and doctors are increasingly aware of our unique Light Adjustable Lens and choosing it for the high-quality, customizable vision it provides,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “The light adjustment infrastructure that we are building in collaboration with a growing number of doctors and practices continues to mature, with expanding clinical, commercial and technical capabilities. We are confident these investments will lead to even better outcomes for patients, durable financial benefits for our customers and our continued growth in 2023 and beyond.”

 

The Company’s fourth quarter and full-year 2022 financial and operational results are preliminary and are subject to the completion of the Company’s 2022 audit. Audited full-year 2022 and unaudited fourth quarter 2022 financial results are anticipated to be announced in early March 2023.

 

About RxSight, Inc.

RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize

img261313502_0.jpg 

and optimize visual acuity for patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

 

Forward-Looking Statements

 

This press release contains forward-looking statements, including statements concerning our preliminary unaudited fourth quarter and fiscal 2022 financial and operational results and the anticipated timing of announcing audited full-year 2022 and unaudited fourth quarter 2022 financial results, patient and doctor awareness of the LAL, the maturation of the Company’s light adjustment infrastructure with expanding clinical, commercial and technical capabilities and anticipated continued growth in 2023 and beyond. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. Investors should review the risks and uncertainties contained in our filings with the Securities and Exchange Commission (“SEC”), including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the SEC on November 7, 2022, as well as other risks set forth in our other filings with the SEC. We caution you that the forward-looking information presented in this press release is not a guarantee of future events, and that actual events may differ materially from those described in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.



The foregoing financial and operational results are preliminary estimates. We are in the process of finalizing our financial statements for the year ended December 31, 2022, and our actual results remain subject to completion of those financial statements and their audit by our independent registered public accounting firm. These preliminary estimates are based on information available to management as of the date of this press release and certain related assumptions, which could prove incorrect. Our actual, reported results of operations could differ based on completion of our year end closing procedures, final adjustments and developments that may arise prior to completion of our annual financial statements, and adjustments arising from the audit by our independent registered public accounting firm. You should carefully review our audited, consolidated financial statements for the year ended December 31, 2022 when they become available.



 

Company contact:

Shelley B. Thunen

Chief Financial Officer

sthunen@rxsight.com

img261313502_0.jpg 

 

Investor Relations Contact:

IR@rxsight.com

 

 

 GRAPHIC 3 img261313502_0.jpg GRAPHIC begin 644 img261313502_0.jpg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end EX-101.PRE 4 rxst-20230108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 5 rxst-20230108.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 rxst-20230108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Jan. 08, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 08, 2023
Entity Registrant Name RxSight, Inc.
Entity Central Index Key 0001111485
Entity Emerging Growth Company true
Securities Act File Number 001-40690
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3268801
Entity Address, Address Line One 100 Columbia
Entity Address, City or Town Aliso Viejo
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92656
City Area Code 949
Local Phone Number 521-7830
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol RXST
Security Exchange Name NASDAQ
XML 8 rxst-20230108_htm.xml IDEA: XBRL DOCUMENT 0001111485 2023-01-08 2023-01-08 false 0001111485 8-K 2023-01-08 RxSight, Inc. DE 001-40690 94-3268801 100 Columbia Aliso Viejo CA 92656 949 521-7830 false false false false Common Stock, par value $0.001 per share RXST NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports rxst-20230108.htm rxst-20230108.xsd rxst-20230108_lab.xml rxst-20230108_pre.xml rxst-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rxst-20230108.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "rxst-20230108.htm" ] }, "labelLink": { "local": [ "rxst-20230108_lab.xml" ] }, "presentationLink": { "local": [ "rxst-20230108_pre.xml" ] }, "schema": { "local": [ "rxst-20230108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rxst", "nsuri": "http://rxsight.com/20230108", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rxst-20230108.htm", "contextRef": "C_096f5381-6010-477c-b2bf-0511cff84f9a", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rxst-20230108.htm", "contextRef": "C_096f5381-6010-477c-b2bf-0511cff84f9a", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rxsight.com/20230108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-000394-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-000394-xbrl.zip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end